Thoracic manifestations of IgG4 ‐related disease
Respirology · 2023-02 · 28 (2) · 120-131
DOI: 10.1111/resp.14422 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Respirology, online erschienen am 27.11.2022. Verfasst von Romain Muller und 7 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, Hopital La Timone, APHM, Aix Marseille University, Marseille, France. Hauptthemen laut MEDLINE: Immunoglobulin G4-Related Disease, Lymphadenopathy. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immunoglobulin G4‐related disease (IgG4‐RD) is a recently described rare systemic fibroinflammatory disease with an estimated incidence of less than 1 in 100,000 persons per year. The disease can affect virtually any organ and is characterized by unifying histopathological findings. Recently, four subgroups of patients have been characterized: hepatobiliary, head and neck, Mikulicz syndrome and retroperitoneal fibrosis, who illustrate the mainly abdominal and ENT tropism of the disease. Yet, thoracic involvement is not uncommon. It can be detected in up to 30% of patients with systemic IgG4‐RD and is the exclusive manifestation of the disease in about 10% of cases. Clinical symptoms are nonspecific and may include dyspnoea, cough or chest pain. Chest CT findings are heterogeneous and primarily include peribronchovascular thickening, nodules, ground‐glass opacities and lymphadenopathy. There is no specific diagnostic test for IgG4‐RD thoracic involvement, which may mimic malignancy or vasculitis. Therefore, a cautious approach is needed to make an accurate diagnosis: a search for extra‐thoracic manifestations, elevated serum IgG4 levels, circulating levels of plasmablasts and pathologic evidence of disease is warranted. Although very suggestive, neither the presence of a polyclonal IgG4 lymphoplasmacytic infiltrate, storiform fibrosis or obliterative phlebitis are sufficient to confirm the histological diagnosis. Steroids are recommended as first‐line therapy. Rituximab or disease‐modifying antirheumatic drugs may be used in relapsed or rare cases of steroid‐refractory disease. In this review, we summarize current knowledge regarding the pathophysiology, epidemiology, diagnostic modalities (clinical–biological–imaging–histopathology) and treatment of IgG4‐RD thoracic involvement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine Department, Hopital La Timone, APHM, Aix Marseille University, Marseille, France.
- Imaging Department, Hopital Nord, APHM, Aix Marseille University, Marseille, France.
- LIIE (Experimental Interventional Imaging Laboratory), Aix Marseille University, Marseille, France.
- Anatomopathology Department, APHM, Aix Marseille University, Marseille, France.
- Pneumology Department, Hopital Nord, APHM, Aix Marseille University, Marseille, France.
- Imaging Department, Hopital La Timone, APHM, Aix Marseille University, Marseille, France.
ORCID-Profile: Romain Muller
Zitieren
APA
Muller, R., Ebbo, M., Habert, P., Daniel, L., Briantais, A., Chanez, P., Gaubert, J. Y., & Schleinitz, N. (2023). Thoracic manifestations of IgG4 ‐related disease. Respirology, 28(2), 120-131. https://doi.org/10.1111/resp.14422
Vancouver
Muller R, Ebbo M, Habert P, Daniel L, Briantais A, Chanez P, et al. Thoracic manifestations of IgG4 ‐related disease. Respirology. 2023;28(2):120-131. doi:10.1111/resp.14422
BibTeX
@article{Muller2023,
author = {Muller, Romain and Ebbo, Mikael and Habert, Paul and Daniel, Laurent and Briantais, Antoine and Chanez, Pascal and Gaubert, Jean Yves and Schleinitz, Nicolas},
title = {Thoracic manifestations of IgG4 ‐related disease},
journal = {Respirology},
year = {2023},
volume = {28},
number = {2},
pages = {120--131},
doi = {10.1111/resp.14422}
}
EUVIMED